Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 20
- Registration Number
- NCT00311883
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 755
- Registration Number
- NCT00259610
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Plaquenil for Alopecia Areata, Alopecia Totalis
- Conditions
- Alopecia Areata
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- Hordinsky, Maria K., MD
- Target Recruit Count
- 16
- Registration Number
- NCT00176982
- Locations
- 🇺🇸
State University of New York at Stony Brook, Stonybrook, New York, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus
- Conditions
- Lichen Planus, Oral
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Target Recruit Count
- 74
- Registration Number
- NCT00102557
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- Graft Versus Host Disease
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 82
- Registration Number
- NCT00031824
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
🇺🇸Maine Children's Cancer Program, Scarborough, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.